Country: Canada
Language: English
Source: Health Canada
MEGLUMINE IOXITALAMATE; SODIUM IOXITALAMATE
LIEBEL-FLARSHEIM CANADA INC
V08AA05
IOXITALAMIC ACID
513MG; 255MG
SOLUTION
MEGLUMINE IOXITALAMATE 513MG; SODIUM IOXITALAMATE 255MG
ORAL
120ML
Ethical
ROENTGENOGRAPHY
Active ingredient group (AIG) number: 0226824001; AHFS:
CANCELLED POST MARKET
2020-08-07
Page 1 of 21 PRESCRIBING INFORMATION NAME OF DRUG: TELEBRIX ® 38 ORAL PROPER NAME: Meglumine Ioxitalamate and Sodium Ioxitalamate Oral Solution 77% PHARMACOLOGY CLASSIFICATION: Oral Radiopaque Contrast Medium for Dilution Liebel-Flarsheim Canada Inc. Pointe-Claire, Quebec, H9R 5H8 Canada Control No. 203737 Revised: August 24 , 2017 Page 2 of 21 NAME OF DRUG Telebrix ® 38 Oral (Meglumine Ioxitalamate and Sodium Ioxitalamate Oral Solution 77% w/v) THERAPEUTIC CLASSIFICATION Oral Radiopaque Contrast Medium for Dilution ACTION When diluted to a 2% solution as directed, Telebrix ® 38 Oral is an oral contrast medium for use as a bowel opacifier during CT scanning of the abdomen and pelvis. A bowel lumen which is adequately opacified with contrast medium facilitates interpretation of the anatomy of the image and permits differentiation of bowel loops from soft tissue masses. INDICATION Telebrix ® 38 Oral is indicated as a bowel opacifier during CT scanning of the abdomen and pelvis. CONTRAINDICATIONS Hypersensitivity to ioxitalamate acid salts or to any of the excipients Severe oliguria or anuria History of major immediate or delayed skin reaction (see ADVERSE REACTIONS section) to Telebrix ® 38 Oral administration If a broncho-esophageal fistula or a risk of aspiration is suspected, hyperosmolar monomeric ionic contrast agents are contraindicated because of the risk of intra-alveolar edema Manifest thyrotoxicosis WARNINGS THIS MEDICINAL PRODUCT MUST NOT BE INJECTED. Allergic reaction is possible regardless of the administration route and dose. Administration by oral route generally leads to very limited systemic diffusion; if the gastrointestinal mucosa is normal, only 5% maximum of the dose administered is found in the urine, the remainder being eliminated with the feces. However, if the gastrointestinal mucosa is altered, absorption is increased; it becomes total and rapid in the event of perforation, with passage into the peritoneal cavity. The medicinal product is then eliminated with the u Read the complete document